Phase 1/2 study of pacritinib, a next generation JAK2/FLT3...

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
9
Language:
english
Journal:
Journal of Hematology & Oncology
DOI:
10.1186/s13045-016-0367-x
Date:
December, 2016
File:
PDF, 576 KB
english, 2016
Conversion to is in progress
Conversion to is failed